NLRP3 deficiency in mice, treatment with the NLRP3 inflammasome inhibitor MCC950/CRID3, and intracerebroventricular injection of NLRP3 siRNAs all ameliorated clinical outcomes in experimental models of stroke (Ma et al, 2014; Yang et al, 2014; Yuan et al, 2015; Ismael et al, 2018b). This evidence concerns the gene NLRP3 and hyperinsulinemic hypoglycemia, familial, 4.